Areas where scientific evidence is lacking or incomplete.
No DSIP gene, precursor, or well-characterised membrane receptor has been found in ~50 years.
Implications: The mechanism stays an unresolved riddle; targeted development is near-impossible without it.
Most human data is from the 1970s-80s, often tiny (5-6 subjects), open-label or uncontrolled.
Implications: There is an absolute lack of modern double-blind RCTs for sleep, pain, or withdrawal; key sleep effects failed to replicate.
Rodent HPA/cortisol suppression did not reproduce in humans; cellular/antioxidant claims are animal/in-vitro only.
Implications: Human cellular-protective and stress effects are unverified.
Plasma half-life is 7-8 minutes, yet effects persist for nights or take weeks to manifest.
Implications: A cascade or programming mechanism is hypothesised but the long-term homeostatic adjustments are undocumented.
Long-term safety is unknown, immunogenicity risk from impurities is high, and no standardised approved dosing exists.
Implications: Clinicians rely on historical IV data or experimental wellness protocols.
Expert disagreements and competing evidence.
DSIP increases delta-wave sleep and reduces sleep onset, restoring natural architecture.
1980s trials and vendor framing.
Independent labs (Obal, Kovalzon, Borbely) failed to replicate it; some saw impaired sleep or wakefulness.
Failed replications; the name is called a misnomer.
Verdict Note
Early positive reports were not reproduced; some studies saw paradoxical wakefulness.
DSIP reduces basal ACTH and suppresses stress cortisol/corticosterone (rodent models).
Preclinical rodent data, ~30% corticosterone drop.
A double-blind placebo-controlled human trial found absolutely no effect on ACTH or cortisol.
Human RCT (PMID 7777652), 3-4 mg IV, identical to placebo.
Verdict Note
Rodent suppression did not translate; the best human trial found zero effect.
DSIP lacks direct opioid-receptor binding and acts as an indirect Met-enkephalin secretagogue.
Radioligand assays show no direct binding.
Some sources suggest direct agonistic, or even antagonistic, activity on opiate receptors.
A study title claims agonism; another claims dependence-inhibiting antagonism.
Verdict Note
Weight of evidence: no direct binding, acts via Met-enkephalin release.
DSIP is incredibly safe, with no lethal dose found and only mild transient side effects.
Animal LD50 absence; mild human side effects.
The FDA lists it as posing significant safety risks, chiefly immunogenicity.
FDA compounding-hazard flag.
Verdict Note
No animal LD50, but the FDA flags serious immunogenicity risk.
Plasma/CSF DSIP levels are higher in MDD patients.
Some biomarker studies.
Other data show levels are lower in MDD than controls.
Conflicting biomarker studies.
Verdict Note
Direction of change conflicts across studies.
DSIP should deepen anesthesia given its sleep-promoting reputation.
Mechanistic hypothesis.
Human administration increased heart rate and reduced anesthesia depth.
Human study outcome.
Verdict Note
Human data contradicts the sleep-based hypothesis.